ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
Automated Covalent Microcontact Bioprinting of Lubricant-Infused Microarrays for Biological Assays.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Automated Covalent Microcontact Bioprinting of Lubricant-Infused Microarrays for Biological Assays.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Microcontact bioprinting (µCP), which utilizes elastomeric stamps to transfer biorecognition agents (bioinks) onto substrates, offers advantages such as customizability, cost-effectiveness, and versatility for bioassays. Despite its prevalent use in laboratory settings, µCP faces challenges in achieving the repeatability and reproducibility required for industrial applications. Here, a µCP method is introduced that accommodates the immobilization of various biorecognition agents, while preserving bioactivity for use in bioassays. A key innovation lies in combining µCP with fluorosilanization to enable lubricant-infused surfaces that prevent non-specific attachment, while concurrently enhancing biomolecule immobilization via covalent attachment through a modified bioink formulation. Furthermore, an automated µCP system is integrated, taking critical steps toward industrial scalability. Following optimization with fluorescent proteins, bacterial viruses (bacteriophages) are printed. The bioactivity preservation is confirmed using Pseudomonas aeruginosa bacteriophage microarrays. A bacterial metabolic activity bioassay is conducted, whereby bacteriophage lytic activity led to a visible color difference after 3 h. The introduced µCP is high-throughput, scalable, and highly customizable, demonstrating strong potential for industrial implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.